Exhibit 99.2

Aditxt Inc.

Unaudited Pro Forma Consolidated Financial Statements

(In U.S. dollars)

June 30, 2024

Aditxt Inc.

Pro Forma Consolidated Statement of Financial Position

(Unaudited)

(In thousands of U.S. dollars)

As at June 30, 2024

	Aditxt		Evofem		Appili (Note 3)		Pro Forma adjustments			Notes	Pro Forma consolidated
	$		$		$		$				$
ASSETS
CURRENT ASSETS:
Cash		91		-		220		12,104		5(a)		12,415
Restricted Cash		-		692		-		-				692
Accounts receivable, net		407		4,617		1,287		-				6,311
Inventory		566		1,060		-		-				1,626
Prepaid expenses		443		845		85		-				1,373
Other receivable		-		-		19		-				19
TOTAL CURRENT ASSETS		1,507		7,214		1,611		12,104				22,436
Fixed assets, net		1,864		1,187		20		-				3,071
Intangible assets, net		8		-		-		6,275		5(b)		6,283
Deposits		107		-		-		-				107
Right of use asset - long term		1,611		114		-		-				1,725
Other assets		-		36		-		-				36
Goodwill		-		-		-		134,849		5(c)		134,849
Investment in Evofem / Appili		23,277		-		-		(23,277	)	5(d)		-
TOTAL ASSETS		28,374		8,551		1,631		129,951				168,507

	Aditxt			Evofem			Appili (Note 3)			Pro Forma Adjustments			Notes	Pro Forma Consolidated
	$			$			$			$				$
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable and accrued expenses		13,139			24,065			3,305			2,600		5(e)		43,109
Notes payable - related party		467			-			-			-				467
Notes payable, net of discount		5,946			397			-			-				6,343
Financing on fixed assets		148			-			-			-				148
Deferred rent		131			-			-			-				131
Convertible notes payable carried at fair value		-			13,239			-			(13,239	)	5(e)		-
Convertible notes payable - Adjuvant		-			29,646			-			(29,646	)	5(e)		-
Derivative liabilities		-			942			-			(942	)	5(e)		-
Other current liabilities		-			3,776			-			-				3,776
Other current liabilities - related party		-			1,000			-			(1,000	)	5(e)		-
Corporate taxes payable		-			-			31			-				31
Long-term debt - current		-			-			6,723			-				6,723
Lease liability - current		735			113			-			-				848
TOTAL CURRENT LIABILITIES		20,566			73,178			10,059			(42,227	)			61,576
Settlement liability		720			-			-			-				720
Long-term debt – non-current		-			-			621			-				621
Lease liability - long term		745			1			-			-				746
TOTAL LIABILITIES		22,031			73,179			10,680			(42,227	)			63,663
Convertible and redeemable preferred stock		-			4,687			-			76,786		5(f)		81,473
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock		2			8			-			(8	)	5(g)		2
Treasury stock		(202	)		-			-			-				(202	)
Additional paid-in capital		156,790			823,709			44,719			(847,942	)	5(g)		177,276
Accumulated other comprehensive income (loss)		-			(781	)		260			521		5(g)		-
Accumulated deficit		(150,024	)		(892,251	)		(54,028	)		942,821		5(g)		(153,482	)
		6,566			(69,315	)		(9,049	)		95,392				23,594
NON-CONTROLLING INTEREST		(223	)		-			-			-				(223	)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)		6,343			(69,315	)		(9,049	)		95,392				23,371
TOTAL LIABILITIES, CONVERTIBLE AND REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)		28,374			8,551			1,631			129,951				168,507

The accompanying notes are an integral part to these unaudited pro forma consolidated financial statements.

1

Aditxt Inc.

Pro Forma Consolidated Statement of Earnings

(Unaudited)

(In thousands of U.S. dollars, except shares and earnings per share)

For the six months ended June 30, 2024

	Aditxt			Evofem			Appili (Note 3)			Pro Forma Adjustments			Notes	Pro Forma Consolidated
	$			$			$			$				$
REVENUE
Sales		124			7,763			8			-				7,895
Cost of goods sold		89			1,453			-			-				1,542
Gross profit		35			6,310			8			-				6,339
OPERATING EXPENSES
Research and development		9,699			864			2,669			-				13,231
Sales and marketing		65			4,588			15			-				4,668
General and administrative expenses		7,783			5,091			1,164			-				14,038
Total operating expenses		17,547			10,543			3,848			-				31,937
NET LOSS FROM OPERATIONS		(17,512	)		(4,233	)		(3,840	)		-				(25,584	)
OTHER INCOME/(EXPENSE)
Interest expense		(3,581	)		-			-			-				(3,581	)
Interest income		1			10			1			-				12
Other expense, net		-			(1,174	)		(135	)		-				(1,309	)
Amortization of debt discount		(1,192	)		-			-			-				(1,192	)
Amortization of intangible assets		-			-			-			(293	)	5(h)		(293	)
Loss on issuance of financial instruments		-			(3,300	)		-			3,300		5(h)		-
Gain on debt extinguishment		-			1,120			-			(1,120	)	5(h)		-
Change in fair value of financial instruments		-			4,127			-			(4,127	)	5(h)		-
Financing costs		-			-			(1,188	)		-				(1,188	)
Government assistance		-			-			3,190			-				3,190
Loss on note exchange agreement		(209	)		-			-			-				(209	)
Total other income/(expense)		(4,981	)		783			1,868			(2,240	)			(4,570	)
Net loss before income taxes		(22,493	)		(3,450	)		(1,972	)		(2,240	)			(30,154	)
Income tax expense		-			(8	)		(7	)		-				(15	)
NET LOSS		(22,493	)		(3,458	)		(1,979	)		(2,240	)			(30,169	)
NON-CONTROLLING INTEREST LOSS		(213	)		-			-			-				(213	)
NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES		(22,279	)		(3,458	)		(1,979	)		(2,240	)			(29,956	)
Deemed Dividend		-			(94	)		-			94		5(h)		-
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		(22,279	)		(3,552	)		(1,979	)		(2,146	)			(29,956	)
NET LOSS per share:
Basic	$	(13.05	)											$	(14.69	)
Diluted	$	(13.05	)											$	(14.69	)
Weighted average number of shares:
Basic		1,707,155													2,040,031
Diluted		1,707,155													2,040,031

The accompanying notes are an integral part to these unaudited pro forma consolidated financial statements.

2

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

1 Description of Transactions

Acquisition of Appili Therapeutics Inc. by Aditxt Inc.:

On December 12, 2023, Aditxt Inc. (“Aditxt”), through its wholly owned subsidiary, Adivir, Inc. (“Adivir”), entered into an agreement to acquire all of the outstanding Class A common shares of Appili Therapeutics Inc. (“Appili”) by way of a court approved plan of arrangement under the Canada Business Corporations Act and a definitive arrangement agreement entered between Appili and Adivir (the “Appili Transaction”). Upon closing of the Appili Transaction, Appili will become an indirect, wholly owned subsidiary of Aditxt. As part of the acquisition terms, Appili shareholders will receive 0.002745004 of a share of Aditxt common stock (the “Share Consideration”) and US$0.0467 in cash for each Appili share held (the “Cash Consideration” and together with Share Consideration collectively, the “Appili Transaction Consideration”), representing total consideration of approximately $6,582 based on closing price of the Aditxt shares on July 5, 2024. The consideration for acquiring Appili also included the assumption of Appili’s existing liabilities.

Acquisition of Evofem Biosciences by Aditxt:

On December 11, 2023, Aditxt, through a definitive agreement, entered into an Agreement and Plan of Merger, as amended and restated, with Evofem Biosciences, Inc. ("Evofem") whereby Evofem will merge with a merger sub with Evofem surviving as as a wholly owned subsidiary of Aditxt (the “Evofem Transaction” and together with the Appili Transaction collectively, “the Transactions”)). The consideration for acquiring Evofem includes the issuance or exchange of convertible preferred stock of $91,610, and cash consideration of $1,800 to Evofem’s common stockholders, along with paying off Evofem’s senior secured notes amounting to $13,045 and the assumption of Evofem's existing liabilities.

On July 12, 2024 (the “Closing Date” of the Amended and Restated Merger Agreement), the Company completed the Initial Parent Equity Investment (as defined under the Merger Agreement) and entered into a Securities Purchase (the “Series F-1 Securities Purchase Agreement”) with Evofem, pursuant to which the Company purchased 500 shares of Evofem’s Series F-1 Convertible Preferred Stock par value $0.0001 per share (“EvoFem F-1 Preferred Stock”) for an aggregate purchase price of $500. In connection with the Series F-1 Securities Purchase Agreement, the Company and Evofem entered into a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which EvoFem agreed to file with the SEC a registration statement covering the resale of the shares of its common stock issuable upon conversion of the Evofem Series F-1 Preferred Stock within 300 days of the Closing Date and to have such registration statement declared effective by the SEC the earlier of the (i) 90th calendar day after the Closing Date and (ii) 2nd Business Day after the date EvoFem is notified (orally or in writing, whichever is earlier) by the SEC that such registration statement will not be reviewed or will not be subject to further review. Pursuant to the Merger Agreement, the Company is also obligated to purchase an additional 3,500 shares of EvoFem Series F-1 Preferred Stock for an additional aggregate purchase price of $3,500 on or prior to September 30, 2024.

2 Basis of preparation

The accompanying unaudited Pro Forma Consolidated Financial Statements of Aditxt, have been prepared to give effect to the acquisitions of Evofem and Appili under the acquisition method of accounting in accordance with ASC Topic 805 – Business Combinations (“ASC 805”). The unaudited Pro Forma Consolidated Statement of Financial Position gives effect to the transactions as if they had occurred on June 30, 2024. The unaudited Pro Forma Consolidated Statement of Earnings for the six months ended June 30, 2024, gives effect to the transactions as if they had occurred on January 1, 2023. The unaudited Pro Forma Consolidated Statement of Financial Position combines the unaudited interim condensed consolidated statement of financial position of Aditxt as at June 30, 2024, with the unaudited interim condensed consolidated statement of financial position of Evofem as at June 30, 2024, and the adjusted unaudited interim condensed consolidated statement of financial position of Appili as at June 30, 2024 (see Note 3).

3

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

2 Basis of preparation (continued)

The unaudited Pro Forma Consolidated Financial Statements are based on, and should be read in conjunction with:

● the audited consolidated financial statements of Aditxt as at and for the year ended December 31, 2023 (“Aditxt’s 2023 Annual Consolidated Financial Statements”) prepared in U.S. dollars and in accordance with accounting principles generally accepted in the United States (“US GAAP);

● the audited consolidated financial statements of Evofem as at and for the year ended December 31, 2023 (“Evofem’s 2023 Annual Consolidated Financial Statements”) prepared in U.S. dollars and in accordance with US GAAP;

● the unaudited interim condensed consolidated financial statements of Aditxt as at and for the six months ended June 30, 2024 (“Aditxt’s 2024 Interim Condensed Consolidated Financial Statements”) prepared in U.S. dollars and in accordance with accounting principles generally accepted in the United States (“US GAAP);

● the unaudited interim condensed consolidated financial statements of Evofem as at and for the six months ended June 30, 2024 (“Evofem’s 2024 Interim Condensed Consolidated Financial Statements”) prepared in U.S. dollars and in accordance with accounting principles generally accepted in the United States (“US GAAP);

● the audited consolidated financial statements of Appili as at and for the year ended March 31, 2024 (Appili’s 2024 Annual Consolidated Financial Statements”) prepared in Canadian Dollars (“CAD”) and in accordance with Internation Financial Reporting Standards (“IFRS”); and

● the unaudited interim condensed consolidated financial statements of Appili as at and for the three months ended June 30, 2024 (“Appili 2024 Interim Condensed Consolidated Financial Statements”) prepared in CAD and in accordance with IFRS.

For the purposes of preparing the unaudited Pro Forma Consolidated Financial Statements, adjustments have been made to align the financial information to US GAAP and convert to U.S. dollars (see note 3).

The unaudited Pro Forma Consolidated Financial Statements have been presented for illustrative purposes only. The pro forma information is not necessarily indicative of what the combined company’s financial position or financial performance would have been had the transactions been completed as at the dates indicated above, nor does it purport to project the future financial position or operating results of the combined company. The unaudited Pro Forma Consolidated Financial Statements do not reflect potential cost savings, operating synergies, and revenue enhancements that may be realized from the transactions. The actual financial position and results of operations of Aditxt for any period following the closing of the transactions may vary from the amounts set forth in the unaudited Pro Forma Consolidated Financial Statements, and such variations could be material.

4

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

2 Basis of preparation (continued)

The pro forma adjustments are based upon available information and certain assumptions believed to be reasonable under the circumstances. The purchase price allocation and the corresponding fair value adjustments are provisional and subject to refinement as more detailed analyses are completed and additional information about the fair value of assets acquired and liabilities assumed becomes available. Aditxt will finalize all amounts as it obtains the necessary information to complete the measurement process, which will be no later than one year from the closing of the transactions. Accordingly, the pro forma adjustments are preliminary and have been made solely for the purpose of providing the unaudited Pro Forma Consolidated Financial Statements. Differences between these preliminary estimates and the final acquisition accounting may occur, and these differences could be material to the accompanying unaudited Pro Forma Consolidated Financial Statements and Aditxt’s future financial performance and financial position.

3 IFRS to US GAAP Reconciliation

For the purposes of preparing the unaudited Pro Forma Interim Consolidated Financial Statements, adjustments have been made to align the financial information of Appili to US GAAP and convert to U.S. dollars as detailed below.

As the ending date of the fiscal period for Appili differs from that of Aditxt, adjustments were made to combine the historical results of Appili for the year ended March 31, 2024, with the three months period ended June 30, 2024, resulting in a recreated statement of earnings for the six months ended June 30, 2024, as summarized below:

Appili Therapeutics Inc Consolidated Balance Sheet	As reported on June 30, 2024		US GAAP Adjustments		Notes	As at June 30, 2024		Currency Translation Adjustments			Notes		As at June 30, 2024
	(IFRS)					(US GAAP)							(US GAAP)
	(CAD)					(CAD)							(U.S. Dollars)
		$					$							$
Assets
Current Assets
Cash		301					301		(81	)		(b)		220
Accounts receivable		1,762					1,762		(475	)		(b)		1,287
Other receivable		26					26		(7	)		(b)		19
Prepaid expenses		117					117		(32	)		(b)		85
		2,206		-			2,206		(595	)				1,611
Non-Current Assets
Fixed assets, net		27					27		(7	)		(b)		20
Total Assets		2,233		-			2,233		(602	)				1,631

5

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

3 IFRS to US GAAP Reconciliation (continued)

Appili Therapeutics Inc Consolidated Balance Sheet	As reported on June 30, 2024			US GAAP Adjustments		Notes	As at June 30, 2024			Currency Translation Adjustments			Notes		As at June 30, 2024
	(IFRS)						(US GAAP)								(US GAAP)
	(CAD)						(CAD)								(U.S. Dollars)
		$						$								$
Liabilities
Current Liabilities
Accounts payable and accrued expenses		4,524						4,524			(1,219	)		(b)		3,305
Long-term debt - current		9,202						9,202			(2,479	)		(b)		6,723
Corporate taxes payable		43						43			(12	)		(b)		31
		13,769			-			13,769			(3,710	)				10,059
Non-Current liabilities
Long-term debt - non-current		850						850			(229	)		(b)		621
Total Liabilities		14,619			-			14,619			(3,939	)				10,680
Shareholder’s Equity
Additional paid-in capital		-						-			44,719			(c)		44,719
Accumulated deficit		(12,386	)					(12,386	)		(41,642	)		(c)		(54,028	)
Currency translation adjustments		-									260			(d)		260
Total Shareholder’s Equity		(12,386	)		-			(12,386	)		3,337					(9,049	)
Total Liabilities and Shareholder’s Equity		2,233			-			2,233			(602	)				1,631

6

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

3 IFRS to US GAAP Reconciliation (continued)

Appili Therapeutics Inc	6 months ended June 30, 2024 (Recreated)			US GAAP Adjustments			Notes		6 months ended June 30, 2024			Currency translation adjustments			Notes		6 months ended June 30, 2024
	(IFRS)								(US GAAP)								(US GAAP)
	(CAD)								(CAD)								(U.S. Dollars)
		$								$								$
Income
Sales		11			-					11			(3	)		(e)		8
Interest income		1			-					1			-			(e)		1
		12			-					12			(3	)				9
Expenses
Research and development		3,611			15			(a)		3,626			(957	)		(e)		2,669
Sales and marketing		20			-					20			(5	)		(e)		15
General and administrative expenses		1,582			-					1,582			(418	)		(e)		1,164
Financing costs		1,614			-					1,614			(426	)		(e)		1,188
Government assistance		(4,319	)		(15	)		(a)		(4,334	)		1,144			(e)		(3,190	)
Other income		183			-					183			(48	)		(e)		135
		2,691			-					2,691			(710	)				1,981
Loss before income taxes		(2,679	)		-					(2,679	)		707					(1,972	)
Income tax expense		9			-					9			(2	)		(e)		7
Net loss		(2,688	)		-					(2,688	)		709					(1,979	)

(a) Reflects a presentation conforming adjustment to reclassify recognition of government grant funding relating to research and development activities on conversion from IFRS to US GAAP.

(b) Reflects a currency translation adjustment from CAD to US dollars using the closing exchange rate on June 30, 2024, of 0.7306.

(c) Reflects a currency translation adjustment from CAD to US dollars using the closing historical exchange rate for equity transactions and subsequently carried at historic values.

(d) Reflects a presentation currency translation difference adjustment arising on translation of CAD to US dollars using historical rates.

(e) Reflects a currency translation adjustment from CAD to US dollars using the average exchange rate for the six months ended June 30, 2024, of 0.7360.

7

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

4 Preliminary Purchase Price Allocation

The following is a preliminary fair value estimate of the assets acquired and liabilities assumed by Aditxt in connection with Appili Transaction and Evofem Transaction, reconciled to the purchase price. For any items without a corresponding reference below, book value is assumed to reasonably approximate fair value based on currently available information.

	Notes	Evofem			Appili
		$			$
Assets acquired
Cash			-			220
Restricted cash			692			-
Accounts receivable			4,617			1,287
Inventory			1,060			-
Prepaid expenses			845			85
Other receivable			-			19
Intangible assets	(a)		-			7,037
Fixed assets			1,187			20
Right-of-use assets			114			-
Other assets			36			-
Total Assets			8,551			8,668
Liabilities assumed
Accounts payable and accrued expenses			24,065			3,305
Notes payable, net of discount			397			-
Other current liabilities			3,776			-
Corporate taxes payable			-			31
Long-term debt			-			7,344
Lease liabilities			113			-
			28,351			10,680
Fair value of identifiable net liabilities acquired			(19,800	)		(2,012	)
Goodwill arising on acquisition:
Cash consideration			1,800			6,096
Shares issued			-			486
Convertible preferred shares issued			91,610			-
Notes assumed			13,045			-
Consideration paid			106,455			6,582
Add: fair value of identifiable net liabilities acquired			19,800			2,012
Goodwill arising from transaction	(b)		126,255			8,594

8

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

4 Preliminary Purchase Price Allocation (continued)

(a) A preliminary fair value estimate of $7,037 has been allocated to identifiable intangible assets acquired for the Appili Transaction. Intangibles assets acquired include licences and intellectual property rights to the research and development activities of Appili, with a useful life of 15 years.

(b) A preliminary estimate of $126,255 and $8,594 has been allocated to the goodwill for the Evofem Transaction and the Appili Transaction, respectively. Goodwill is calculated as the excess of the preliminary estimate of the acquisition date fair value of the consideration transferred, over the preliminary estimate of the fair values assigned to the identifiable assets acquired and liabilities assumed.

5 Pro Forma Adjustments in Connection with the Transactions

The following summarizes the pro forma adjustments in connection with the Appili Transaction and the Evofem Transaction to give effect to the transactions as if they had occurred on January 1, 2023, for the purposes of the unaudited Pro Forma Interim Consolidated Statement of Earnings and on June 30, 2024, for the purposes of the unaudited Pro Forma Interim Consolidated Statement of Financial Position. The pro forma adjustments were based on preliminary estimates and assumptions that are subject to change.

(a) Cash

Reflects the pro forma adjustment to cash representing the sources and uses of cash to close the Transactions as if the Transactions had occurred on June 30, 2024. Sources and uses of cash include the $6,096 decrease for the preliminary purchase price paid for the Appili Transaction, $1,800 decrease for the preliminary purchase price paid for the Evofem Transaction, and an increase of $20,000 in proceeds from the issuance of common stock of Aditxt, net of issuance costs.

(b) Intangible Assets

An increase of $7,037 to the carrying value of Appili intangible assets to adjust it to its preliminary estimated fair value and an increase of $762 to the accumulated amortization. Intangibles assets acquired include licences and intellectual property rights to research and development activities of Appili.

(c) Goodwill

Reflects an increase of $126,255 and $8,594 of goodwill as a result of the preliminary purchase price allocation of Evofem Transaction and Appili Transaction, respectively. Goodwill is not amortized and is not currently assumed to be deductible for tax purposes. Goodwill could materially change based on changes in estimates in the fair value of the assets acquired, and liabilities assumed.

9

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

5 Pro Forma Adjustments in Connection with the Transactions (continued)

(d) Investment in Evofem

Reflects a decrease of $23,277 in Investment in Evofem for the elimination of cost of investment in Evofem on consolidation.

(e) Current Liabilities

Accounts payable and accrued expenses: Reflects an increase of $2,600 for transaction costs associated with Evofem Transaction and Appili Transaction.

Convertible notes payable carried at fair value: Reflects a decrease of $13,239 to reflect the settlement of the notes in conjunction with the close of the transaction.

Convertible notes payable – Adjuvant: Reflects a decrease of $29,646 to reflect the settlement of the notes in conjunction with the close of the transaction.

Derivative liabilities: Reflects a decrease of $942 to reflect the settlement of the liability in conjunction with the close of the transaction.

Other current liabilities – related party: On or about May 2, 2024, in connection with a certain Reinstatement and Fourth Amendment to Merger Agreement dated as of May 2, 2024, Aditxt initiated a wire transfer to Evofem to an account previously designated by Evofem in the amount of $1,000, which is disclosed in the Investment in Evofem balance on Aditxt’s consolidated balance sheets. The decrease to this line item is related to eliminating this amount upon consolidation.

(f) Mezzanine Equity

Convertible and redeemable preferred stock: Reflects an increase of $70,751 for the issuance of convertible preferred stock for the Evofem Transaction and $4,687 decrease on elimination of convertible preferred stock of Evofem on consolidation.

(g) Total Equity

Common stock: Reflects the elimination of $8 for the common stock of Evofem.

Additional paid-in capital: Reflects an increase of $20,486 for the issuance of common stock in connection with the Appili Transaction, a $44,719 decrease on elimination of Appili paid-in-capital and a $823,709 decrease on elimination of Evofem paid-in-capital on consolidation.

Accumulated other comprehensive income (loss) adjustment: Reflects a decrease of $260 on elimination of currency translation adjustment on consolidation of Appili and an increase of $781 upon elimination of comprehensive loss of Evofem.

10

Aditxt Inc.

Notes to Pro Forma Consolidated Financial Statements

(Unaudited)

(In thousands of U.S. dollars)

For the six months ended June 30, 2024

5 Pro Forma Adjustments in Connection with the Transactions (continued)

Accumulated deficit: Reflects a $892,251 and $54,028 decrease in accumulated deficit to eliminate historical retained loss of Evofem and Appili, respectively, $586 increase in amortization expense for intangible assets relating to Appili, and $2,600 increase for transaction costs associated with the Appili Transaction and Evofem Transaction.

(h) The unaudited Pro Forma Consolidated Statement of Earnings is also adjusted as follows:

● Increase amortization expense by $293 for amortization of the intangible assets recorded at fair value for the six months ended June 30, 2024.

● Decrease to loss on issuance of financial instruments of $3,300 for the six months ended June 30, 2024 to remove the impact of issuances of purchase rights due to a down-round related to instruments that would have been extinguished as a requirement of the Evofem closing.

● Decrease to gain on debt extinguishment of $1,120 for the six months ended June 30, 2024 to remove the impact of the debt extinguishment related to an instrument that would have been extinguished as a requirement of the Evofem closing.

● Decrease to change in fair value of financial instruments of $4,127 for the six months ended June 30, 2024 to remove the impact of fair value adjustments related to instruments that would have been extinguished as a requirement of the Evofem closing.

● Elimination of $94 related to the Evofem deemed dividend on instruments that would have been extinguished as a requirement of the Evofem closing.

11